PLC () has filed a new patent application for its CDX antibody.
It covers its use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia (AML).
On the latter, the application covers the composition sequences of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells of certain types of leukaemia.
“Filing this patent is an important development and further solidifies Hemogenyx’s leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,” said Hemogenyx chief executive, Dr Vladislav Sandler.
“The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor.”
- The White House wants people of Earth to come together to mine the moon
- Hennessey Jeep Maximus and its 1,000 hp are ready to roll
- PlayStation 5: DualSense controller, release date, specs and everything else we know
- Easter Bunny and Tooth Fairy deemed essential during coronavirus lockdown
- Add an LG Blu-ray player to your home theater for $50
- Xbox Series X specs, backward compatibility and everything we know so far
- Chan Zuckerberg Biohub and UCSF boost Bay Area coronavirus testing
- Coronavirus updates: Wuhan ends lockdown, UK prime minister in stable condition in ICU
- iPhone SE: Every spec, rumor and the expected launch date